SRX Global acquires stake in Vistagen Therapeutics
PUBT · 5h ago
Share
Listen to the news
- SRX Global acquired a stake in Vistagen Therapeutics, taking a minority equity position in the Nasdaq-listed biotech.
- The investment targets Vistagen’s late-stage neuroscience pipeline built around intranasal “pherine” product candidates.
- SRX Global described Vistagen shares as undervalued, signaling plans for engagement with management and the board on value creation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SRX Global Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040500PRIMZONEFULLFEED9802973) on August 04, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved